If you have had a bad reaction to a drug, you might have a right to make a claim for your injuries. Our skilled personal injury attorneys are currently accepting cases for clients who have suffered injuries from the following :


Nephrogenic Systemic Fibrosis (NSF) is a medical condition that has come to be associated with exposure to the element gadolinium, when used as a radiocontrast agent during an MRI.

There is strong support in the medical literature of the cause and effect relationship between Gadolinium-based contrast dyes and NSF. In particular, four of these contrast dyes seem to have been implicated including Omniscan, MultiHance, Magnevist, and OptiMARK

For those afflicted with Nephrogenic Systemic Fibrosis (NSF), a medical condition that has come to be associated with exposure to the element gadolinium, the prospect of an NSF lawsuit can seem daunting. However, it is important to understand that exposure to gadolinium may involve serious negligence, for which one or more parties may be held to account. Therefore, for anyone who has been or has had a loved one afflicted with NSF, it is important to locate an NSF lawyer or an NSF law firm that may serve your interests.


Levaquin (generic levofloxacin) is a powerful, prescription antibiotic made by Ortho-McNeil Pharmaceutical that has been linked to an increased risk of tendon ruptures, tendinitis, and other serious injuries. As part of the group of antibiotics called fluoroquinolones, Levaquin is commonly used to treat bacterial infections of the sinuses, skin, lungs, ears, airways, bones, and joints.

Tendons can rupture quickly, within hours of taking Levaquin, or may take weeks to develop. In some cases, patients feel pain and notice swelling or bruising in the area of the tendon, but some patients report seeing no symptoms of problems before they are injured.

People who have been injured by Levaquin or another type of fluoroquinolone may be eligible to be financially compensated for medical bills, pain and suffering, lost wages, and other damages.


On April 28, 2008, a nationwide Digitek recall was announced for all lots of the heart medication sold throughout the United States. Due to manufacturing defects, Digitek (digoxin tablets) could contain twice the appropriate amount of active ingredients. This could lead to serious and potentially fatal illness caused by overmedication, especially among individuals with renal insufficiencies.

Recalled Medications Include: Digitek, Digoxin, Cardoxin, Lanoxin, and Lanoxicaps. The voluntary all lot recall is due to the possibility that tablets with double the appropriate thickness may have been commercially released. These tablets may contain two times the approved level of active ingredient.

If you are someone you know has been adversely affected by the use of Digitek, please contact our law firm for a free consultation.


In February of 2008, the Food & Drug Administration (FDA) issued a Public Health Advisory warning doctors and other health practitioners not to use Baxter Heparin products. According to the FDA, since the beginning of 2008, it has received 350 reports of side effects linked to Baxter Heparin. The FDA also said that four patients had died after being administered the drug.

Shortly thereafter, the FDA announced that Baxter would be recalling all of its remaining Heparin products. By this time, Baxter Heparin had been implicated in more than 400 life-threatening reactions and could have been responsible for as many as 21 deaths.

Heparin’s side effects involve a variety of symptoms including abdominal pain, decreased blood pressure, burning sensation, chest pain, diarrhea, dizziness, drug ineffectiveness, dyspepsia, dyspnea, erythema, flushing, headache, hyperhidrosis, hypoesthesia, hypotension, loss of consciousness, malaise, nausea, pallor, palpitations, paresthesia, pharyngeal edema, restlessness, vomiting/retching, stomach discomfort, tachycardia, thirst, trismus, and unresponsiveness to stimuli.

Our Heparin injury lawyers have determined that the drug involved in these reactions was defective, and that Baxter’s failure to adequately regulate its suppliers contributed to the Heparin’s defects .

Pain Pumps

The use of intra-articular pain pumps in shoulder surgeries has been associated with a condition called Postarthroscopic Glenohumeral Chondrolysis (PAGCL). PAGCL is the deterioration of cartilage in the shoulder following such procedures. An intra-articular pain pump catheter is placed into the shoulder joint during these procedures. The pain pump remains in the joint for several days to deliver pain medication to the shoulder.

PAGCL is an extremely painful and life-altering condition. Symptoms of PAGCL include increased shoulder stiffness, popping or grinding when the shoulder is in motion, decrease in range of motion, and a loss of strength in the joint. PAGCL is usually diagnosed with an x-ray showing the narrowing of the shoulder joint space. Treatment for this condition is further surgery; however, many patients never regain full use of their shoulder joint.

If you have been adversely harmed by a pain pump, please contact us for a free legal consultation.

Perils of Preemption

Are you aware that your ability to file a state lawsuit for harms suffered, including death, against a pharmaceutical company for failure to warn of hidden but known risks of a potential side-effect of a particular medication may be a thing of the past?

Currently, there are numerous cases in the U.S. Federal Court System that may limit your ability to pursue such a lawsuit. Post-Vioxx, the manufacturers of such medications have been actively engaged in persuading Federal Courts to recognize a legal doctrine called “Preemption” whereby drug manufacturers are considered immune from liability for harms caused by their drugs on the basis that such drugs are approved by the Food and Drug Administration (FDA).

Please contact your Senator and Congressman immediately and voice your opinion against preemption and in favor of maintaining your rights to bring a pharmaceutical lawsuit in state court. Call us to learn more.